Potential circulating markers for the management of kidney cancer

C. Botti, E. Seregni, S. Mattioli, S. Massaron, A. Bonanate, D. Cantarella, E. Bombardieri

Research output: Contribution to journalArticle

Abstract

The prognosis of renal cell carcinoma (RCC) is generally poor. An easier detection of this tumor and a better monitoring of RCC patients would be possible if serum markers with acceptable sensitivity and specificity were available. In RCC, as opposed to other cancers, no circulating serum markers with sufficient renal specificity have been discovered. In fact, even when the hybridoma technology allowed the production of several monoclonal antibodies against RCC structures, none of them led to any available diagnostic immunoassays. Other possible circulating tumor markers of potential application in RCC patients include different substances such as acute phase reactant proteins, enzymes, mucins, cytokeratins, proteins, interleukins, that demonstrated some relationship with the presence and the changes in the RCC evolution. In this general review we report and discuss the results in the literature obtained by serum assays of these substances which have been shown to be of some help for the prognosis and monitoring of RCC. The greater part of these biomolecules are already measured in clinical practice for the management of other malignancies, but their application in RCC could give interesting clinical information.

Original languageEnglish
Pages (from-to)147-157
Number of pages11
JournalInternational Journal of Oncology
Volume10
Issue number1
Publication statusPublished - 1997

Fingerprint

Kidney Neoplasms
Renal Cell Carcinoma
Acute-Phase Proteins
Biomarkers
Neoplasms
Interleukins
Practice Management
Hybridomas
Mucins
Tumor Biomarkers
Keratins
Immunoassay
Monoclonal Antibodies
Technology
Kidney
Sensitivity and Specificity
Enzymes
Serum

Keywords

  • Circulating tumor markers
  • Kidney cancer
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Botti, C., Seregni, E., Mattioli, S., Massaron, S., Bonanate, A., Cantarella, D., & Bombardieri, E. (1997). Potential circulating markers for the management of kidney cancer. International Journal of Oncology, 10(1), 147-157.

Potential circulating markers for the management of kidney cancer. / Botti, C.; Seregni, E.; Mattioli, S.; Massaron, S.; Bonanate, A.; Cantarella, D.; Bombardieri, E.

In: International Journal of Oncology, Vol. 10, No. 1, 1997, p. 147-157.

Research output: Contribution to journalArticle

Botti, C, Seregni, E, Mattioli, S, Massaron, S, Bonanate, A, Cantarella, D & Bombardieri, E 1997, 'Potential circulating markers for the management of kidney cancer', International Journal of Oncology, vol. 10, no. 1, pp. 147-157.
Botti C, Seregni E, Mattioli S, Massaron S, Bonanate A, Cantarella D et al. Potential circulating markers for the management of kidney cancer. International Journal of Oncology. 1997;10(1):147-157.
Botti, C. ; Seregni, E. ; Mattioli, S. ; Massaron, S. ; Bonanate, A. ; Cantarella, D. ; Bombardieri, E. / Potential circulating markers for the management of kidney cancer. In: International Journal of Oncology. 1997 ; Vol. 10, No. 1. pp. 147-157.
@article{53929964df604e03ae29c5c993d148cb,
title = "Potential circulating markers for the management of kidney cancer",
abstract = "The prognosis of renal cell carcinoma (RCC) is generally poor. An easier detection of this tumor and a better monitoring of RCC patients would be possible if serum markers with acceptable sensitivity and specificity were available. In RCC, as opposed to other cancers, no circulating serum markers with sufficient renal specificity have been discovered. In fact, even when the hybridoma technology allowed the production of several monoclonal antibodies against RCC structures, none of them led to any available diagnostic immunoassays. Other possible circulating tumor markers of potential application in RCC patients include different substances such as acute phase reactant proteins, enzymes, mucins, cytokeratins, proteins, interleukins, that demonstrated some relationship with the presence and the changes in the RCC evolution. In this general review we report and discuss the results in the literature obtained by serum assays of these substances which have been shown to be of some help for the prognosis and monitoring of RCC. The greater part of these biomolecules are already measured in clinical practice for the management of other malignancies, but their application in RCC could give interesting clinical information.",
keywords = "Circulating tumor markers, Kidney cancer, Renal cell carcinoma",
author = "C. Botti and E. Seregni and S. Mattioli and S. Massaron and A. Bonanate and D. Cantarella and E. Bombardieri",
year = "1997",
language = "English",
volume = "10",
pages = "147--157",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - Potential circulating markers for the management of kidney cancer

AU - Botti, C.

AU - Seregni, E.

AU - Mattioli, S.

AU - Massaron, S.

AU - Bonanate, A.

AU - Cantarella, D.

AU - Bombardieri, E.

PY - 1997

Y1 - 1997

N2 - The prognosis of renal cell carcinoma (RCC) is generally poor. An easier detection of this tumor and a better monitoring of RCC patients would be possible if serum markers with acceptable sensitivity and specificity were available. In RCC, as opposed to other cancers, no circulating serum markers with sufficient renal specificity have been discovered. In fact, even when the hybridoma technology allowed the production of several monoclonal antibodies against RCC structures, none of them led to any available diagnostic immunoassays. Other possible circulating tumor markers of potential application in RCC patients include different substances such as acute phase reactant proteins, enzymes, mucins, cytokeratins, proteins, interleukins, that demonstrated some relationship with the presence and the changes in the RCC evolution. In this general review we report and discuss the results in the literature obtained by serum assays of these substances which have been shown to be of some help for the prognosis and monitoring of RCC. The greater part of these biomolecules are already measured in clinical practice for the management of other malignancies, but their application in RCC could give interesting clinical information.

AB - The prognosis of renal cell carcinoma (RCC) is generally poor. An easier detection of this tumor and a better monitoring of RCC patients would be possible if serum markers with acceptable sensitivity and specificity were available. In RCC, as opposed to other cancers, no circulating serum markers with sufficient renal specificity have been discovered. In fact, even when the hybridoma technology allowed the production of several monoclonal antibodies against RCC structures, none of them led to any available diagnostic immunoassays. Other possible circulating tumor markers of potential application in RCC patients include different substances such as acute phase reactant proteins, enzymes, mucins, cytokeratins, proteins, interleukins, that demonstrated some relationship with the presence and the changes in the RCC evolution. In this general review we report and discuss the results in the literature obtained by serum assays of these substances which have been shown to be of some help for the prognosis and monitoring of RCC. The greater part of these biomolecules are already measured in clinical practice for the management of other malignancies, but their application in RCC could give interesting clinical information.

KW - Circulating tumor markers

KW - Kidney cancer

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0031024561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031024561&partnerID=8YFLogxK

M3 - Article

C2 - 21533358

AN - SCOPUS:0031024561

VL - 10

SP - 147

EP - 157

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 1

ER -